Accession | SAMC1941443 |
---|---|
Accession in Other Database | GSA-Human: HRS305588 |
Sample name | D180315106478-KY500 |
Title | Resected lung cancer sample S98 |
Sample type | Human sample |
Organism | Homo sapiens |
Description | Targeted sequencing data of resected lung cancer sample of patient D98 |
Attributes | *This sample record contains additional controlled-access information that is avaiable from GSA-Human by requesting study HRA001462 in the GSA-Human system. |
Release date | 2021-10-22 |
BioProject Accession | PRJCA006923 |
Submitter | Si-Yang Liu (momogogogo@126.com) |
Organization | 020-83827812-51311 |
Submission date | 2023-06-18 |
Resource name | Description |
---|---|
GSA-Human (1) | - |
HRA001462 (Controlled Access) | The ADJUVANT study reported comparative superiority of adjuvant gefitinib over chemotherapy in disease-free survival (DFS) of EGFR-mutant resected stage II-IIIA non-small-cell lung cancer (NSCLC). However, inconsistent clinical benefits have necessitated precise genetic categorization for adjuvant guidance. |